Keywords

Ketamine, Esketamine, Depression, Bipolar Disorder, Anhedonia, Suicidal Ideation, SHAPS, MADRS, BSSI

Abstract

This meta-analysis examines the efficacy and effectiveness of racemic ketamine (RS-ketamine) and esketamine in reducing depressive symptoms such as suicidal ideation and anhedonia in patients suffering from treatment-resistant depression and bipolar disorder. This review comprehensively looks at six studies: three clinical studies focusing on suicidal ideation and three looking at anhedonia. Across the studies, RS-ketamine and esketamine were associated with a higher resolution of suicidal ideation, risk, and anhedonia. Significant improvements were noted in the suicidal desire and ideation subscale of the Beck Scale for Suicidal Ideation. The pooled effect size for suicidal ideation (d = 0.533) and pooled effect size for anhedonia (d = 0.97) indicated a moderate-high effect of ketamine in reducing suicidal ideation and anhedonia scores within 24 hours of administration. The results indicate ketamine is advantageous in its fast-acting properties that could benefit patients in acute distress, and ketamine could significantly enhance the success rate of traditional antidepressants when used in conjunction. The findings support ketamine as a promising treatment for treatment-resistant depression and bipolar disorder.

Thesis Completion Year

2024

Thesis Completion Semester

Summer

Thesis Chair

Neal, Raymonde

College

College of Sciences

Department

Department of Psychology

Thesis Discipline

Psychopharmacology

Language

English

Access Status

Open Access

Length of Campus Access

None

Campus Location

Orlando (Main) Campus

Download

Share

COinS
 

Rights Statement

In Copyright